Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BB-1709
- Development stage
- Phase 1
- Lead developer
- 百力司康
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
BB-1709 is an investigational antibody-drug conjugate (ADC) developed by Bliss Biopharmaceutical (Hangzhou). It is designed to target Ecto-5'-nucleotidase (CD73), an enzyme implicated in tumor immune evasion, and also acts as a tubulin inhibitor. By inhibiting Ecto-5'-nucleotidase (CD73) enzymatic activity, BB-1709 may promote anti-tumor immune responses, while its tubulin inhibition disrupts cancer cell division. The drug is currently being evaluated in Phase 1 clinical trials for the treatment of locally advanced or metastatic solid tumors. Preclinical studies have shown favorable safety and efficacy profiles, suggesting potential utility across various solid tumor types.
02
Targets
NT5E (Cluster of Differentiation 73)
Beyond the preview
Go deeper on BB-1709.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BB-1709.